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Abstract
The treatment of uveitis is undergoing significant change as a result of the development of new therapeutic approaches, of which the 
biologic agents form a major part. These targeted therapies have shown great promise for the treatment of refractory disease and some 
have now undergone systematic evaluation through prospective clinical trials, unlike many of their predecessor drugs.
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This last decade has seen truly significant changes in the understanding 
and management of uveitis, from the standardisation of diagnostic 
criteria that the Standardization of Uveitis Nomenclature (SUN) 
project has brought to the advent of novel therapeutic options that 
have revolutionised disease management.1,2 In this, the uveitis world 
is following the lead set by rheumatology in the 1980s, in which 
increasingly scientific disease phenotyping drove better and more 
ambitious clinical trials that in turn drove improvements in clinical 
management and outcomes. This is making it an exciting time to be 
part of uveitis research, and the increasing number of well-designed 
clinical trials is testament to this.
The need for novel treatment options lies in the side-effect profile 
of corticosteroids.  Their ease of use and reliability means that they 
remain the mainstay of initial treatment, particularly when inflammation 
is bilateral or associated with systemic disease, but their side-effect 
profile is significant. Conventional steroid-sparing immunosuppressive 
agents are of variable efficacy and carry their own issues with side-
effects, driving the development of two alternative approaches.
The first of these is the increasing use of local therapy in the form 
of sustained release steroid implants such as the dexamethasone 
implant (Ozurdex®; Allergan, Inc., Irvine, CA, US) and fluocinolone 
implant (Retisert™; Bausch & Lomb Inc., Rochester, NY, US).3,4 These 
have been tested in clinical trials programmes and are very effective 
in some patients, particularly in the absence of systemic disease or 
for unilateral disease. However, they are all currently corticosteroid-
based and thus have associated ocular side-effects such as cataract 
formation and raised intraocular pressure.
The second approach is the development of more targeted systemic 
therapies, namely the biologic agents. In contrast to conventional 
immunosuppressive agents, biologics modulate inflammation by 
targeting specific receptors or single molecules and thus offer a more 
specific suppression of the immune effector response. They are useful 
in patients who fail to respond to conventional immunosuppressive 
therapy,5 and may also reduce the risk of visual loss in severe forms of 
intraocular inflammation, such as uveitis related to Behcet’s disease.6  
The greatest volume of evidence for the biological agents exists for 
the tumour necrosis factor (TNF)-alpha inhibitors. TNF-α has been 
detected in human eyes with a variety of inflammatory conditions and 
its inhibition can be effective in the short and long-term management 
of patients with refractory posterior uveitis.7 The most established drug 
in this class is infliximab (Remicade®; Janssen Biotech, Inc., Horsham, 
PA, US), but the first biologic drug to undergo a formal clinical trial 
programme in uveitis was adalimumab (Humira®; AbbVie Inc. North 
Chicago, IL, US). The development of clinical trials is important, as it 
enables these drugs to move from off-label and ad hoc use to formal 
licensing and national commissioning. Humira is a fully humanised 
monoclonal antibody directed against soluble and membrane-bound 
TNF which has the advantage of being a subcutaneous injection that 
patients can perform at home, rather than requiring hospital admission 
for intravenous infusions.8 Humira was approved by the US Food and 
Drug Administration (FDA) earlier this year, and an application for EU 
marketing authorisation is expected shortly. The drug is also due to be 
part of a UK National Institute for Health and Care Excellence (NICE) 
multiple technology appraisal.
Other biologic agents provide interest, but are at an earlier stage of 
understanding and usage. Interleukin-17 (IL-17) has generated a great 
deal of interest as a possible therapeutic target, but secukinumab, 
a human monoclonal antibody directed against IL-17, failed to 
demonstrate efficacy in early trials in uveitis;9 nevertheless, this 
approach holds out the hope of interrupting a mechanism that may 
be involved in the generation of tolerance.10 Other novel systemic 
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approaches include reducing antigen presentation by blocking lymph 
node efflux via the sphingosine-1-phosphate receptor (fingolimod), 
targeting B cells (rituximab), and reducing inflammatory cell migration 
via α4-integrin (natalizumab).
It is an exciting time in uveitis research – there are more therapeutic 
options than ever before, yet there are also more questions about how 
and when to use them; the future should hold interesting developments 
for researchers, clinicians and patients. ■
1. Jabs DA, Nussenblatt RB, and Rosenbaum JT, Standardization 
of uveitis nomenclature for reporting clinical data. Results 
of the First International Workshop, Am J Ophthalmol, 
2005;140:509–16.
2. de Smet MD, Taylor SR, Bodaghi B, et al., Understanding 
uveitis: the impact of research on visual outcomes, Prog Retin 
Eye Res, 2011;30:452–70.
3. JH Kempen JH, Altaweel MM, Holbrook JT, et al., Randomized 
comparison of systemic anti-inflammatory therapy versus 
fluocinolone acetonide implant for intermediate, posterior, 
and panuveitis: the multicenter uveitis steroid treatment trial, 
Ophthalmology, 2011;118:1916–26.
4. Lowder C, Belfort R Jr, Lightman S, et al., Dexamethasone 
intravitreal implant for noninfectious intermediate or 
posterior uveitis, Arch Ophthalmol, 2011;129:545–53.
5. Joshi L, Lightman SL, Salama AD, et al., Rituximab in refractory 
ophthalmic Wegener’s granulomatosis: PR3 titers may 
predict relapse, but repeat treatment can be effective, 
Ophthalmology, 2011;118:2498–503.
6. Taylor SR, Singh J, Menezo V, et al., Behcet disease: visual 
prognosis and factors influencing the development of visual 
loss, Am J Ophthalmol, 2011;152:1059–66.
7. Benitez-del-Castillo JM, Martinez-de-la-casa JM, et al., 
Long-term treatment of refractory posterior uveitis with anti-
TNFalpha (infliximab), Eye (Lond), 2005;19:841–5.
8. Diaz-Llopis M, Salom D, Garcia-de-Vicuna C, et al., Treatment of 
refractory uveitis with adalimumab: a prospective multicenter study 
of 131 patients, Ophthalmology, 2012;119:1575–81.
9. Dick AD, Tugal-Tutkam, Foster S, et al., Secukinumab in the 
treatment of noninfectious uveitis: results of three randomized, 
controlled clinical trials, Ophthalmology, 2013;120:777–87.
10. Barbi J, Pardoll D, Pan F, Metabolic control of the Treg/Th17 
axis, Immunol Rev, 2013;252:52–77.
Taylor_FINAL.indd   18 03/08/2016   16:53
